TSP-2 is secreted from the fibrotic liver, and we have recently reported that serum TSP-2 is a novel biomarker for detecting NASH, advanced fibrosis, and predicting HCC occurrence among nonalcoholic fatty liver disease (NAFLD) patients [11]. This evidence concerns the gene THBS2 and metabolic dysfunction-associated steatohepatitis.